Join Now

Recent BioUtah News & Events

Everything Happening in Utah Life Sciences

April 7, 2022
BioUtah News
Curavit Named Runner up in BioUtah’s 2022 Entrepreneur & Investor Life Sciences Summit Pitch Competition

Donates Monetary Winnings to Biohive’s Non Profit Work to Bring STEM Education to Underrepresented Communities

April 6, 2022
BioUtah News
NATIONAL INSTITUTES OF HEALTH AWARDS GRANT TO SINTX TECHNOLOGIES FOR DEVELOPMENT OF 3D PRINTED CRANIOMAXILLOFACIAL DEVICES

SINTX Technologies announced a Phase 1 grant of $300k awarded by the National Institutes of Health (NIH) to develop, design and characterize 3D printed implants for craniomaxillofacial (CMF) applications using a composite of silicon nitride and polyetherketoneketone (SN-PEKK).

April 1, 2022
BioUtah News
Updated Interim Data from Clene Nanomedicine’s RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Science Program at 2022 AAN Annual Meeting

Results show significant survival benefit in participants who entered open-label extension of study of CNM-Au8®, a gold nanocrystal suspension, compared to validated ENCALS prediction mode

March 31, 2022
Policy News
Healthcare Priorities of President Biden’s FY23 Budget

On Monday, March 28, President Biden announced his budget for FY23, a $5.8 trillion proposal that reflects the administration’s funding priorities, many of which were drawn from the initial Build Back Better package.  Congress is not required to adopt any or all of the president’s budget. However, each year, the president’s budget proposal serves as […]

March 31, 2022
BioUtah News
March 31, 2022
BioUtah News Policy News
FACT SHEET: The Biden Administration’s Historic Investment in Pandemic Preparedness and Biodefense in the FY 2023 President’s Budget

The Biden Administration’s Investment in Pandemic Preparedness and Biodefense in the FY 2023 President’s Budget

March 31, 2022
BioUtah News
Diversified Medical Healthcare Acquires Utah Lab, Dynasty Medical Laboratory Services

Diversified Medical Healthcare Acquires Utah Lab, Dynasty Medical Laboratory Services

March 31, 2022
BioUtah News
Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes

Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes

March 31, 2022
BioUtah News
Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors

Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors

March 31, 2022
BioUtah News
PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update

SALT LAKE CITY, March 30, 2022 /PRNewswire/ — PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the twelve-month period ended December 31, 2021. Recent Business and Financial Updates In the first quarter of 2022, PolarityTE received approval from the U.S. […]

March 31, 2022
BioUtah News
Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed Capital

The total capital represents the largest seed financing for life science startups in Utah’s history

March 31, 2022
BioUtah News
Halia Therapeutics Presented Data on Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer’s Disease

Halia Therapeutics presented data today on its NLRP3 inhibitor program at today’s 10th Annual Neurodegenerative Drug Development Summit. 

March 31, 2022
BioUtah News
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022

March 24, 2022
Policy News
MDUFA V Agreement Reached

The FDA and representatives from the medical device industry have reached an agreement on proposed recommendations for MDUFA V. On March 22, FDA sent the commitment letter to Congress. Under the new agreement, the FDA would be authorized to collect at least $1.78 billion in user fees over five years. FDA could receive additional funding […]

March 24, 2022
BioUtah News
Pfizer’s $7B bet delivers phase 3 success, advancing bid to establish new drug in ulcerative colitis Arena

Pfizer’s $6.7 billion bet on Arena Pharmaceuticals has delivered a phase 3 success.

March 24, 2022
BioUtah News
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results

Recursion reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2021.

March 24, 2022
BioUtah News
FierceBiotech recognizes Recursion as the #2 Biotech IPO of 2021!

FierceBiotech Special Report: The top 10 biotech IPOs of 2021

March 24, 2022
BioUtah News
Co-Diagnostics Reports Full Year 2021 Financial Results

Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY’22

March 18, 2022
BioUtah News
WATCH THE EXIM BANK & STEP GRANT FUNDS 101 WEBINAR REPLAY

WTC UTAH HAS A RECORD $1M+ TO ADMINISTER TO UTAH SMALL BUSINESSES. Learn from World Trade Center Utah, Meridian Finance Group, and the U.S. Small Business Administration (SBA) about export programs through the Export-Import Bank of the United States (EXIM) and how State Trade Expansion Program (STEP) funds can be used for those programs as a new eligible expense.

March 17, 2022
BioUtah News
Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board

Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board

March 17, 2022
BioUtah News
Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies

Myriad to establish new Walter Gilbert Research and Innovation Center Company also cited among 2022 Top Workplaces USA National List by Energage

March 17, 2022
BioUtah News
Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer

BRACAnalysis CDx is now the only germline test approved by FDA as a companion diagnostic for treatment of HER2 negative high-risk early-stage breast cancer

March 17, 2022
BioUtah News
Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care

Company launches Precise™ Tumor test, part of a comprehensive suite combining germline, tumor and companion diagnostics in one easy-to-access solution

March 17, 2022
BioUtah News
Pfizer Completes Acquisition of Arena Pharmaceuticals

Acquisition offers new, differentiated, and potentially best-in-class approach to address needs of a broader number of patients with immuno-inflammatory diseases